Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been given an average rating of “Moderate Buy” by the eight research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $10.0833.

Several analysts recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, January 21st. Zacks Research downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Piper Sandler raised their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Friday, January 9th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research report on Friday, November 7th.

Insider Activity

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $7.09, for a total transaction of $106,350.00. Following the sale, the director owned 142,500 shares in the company, valued at $1,010,325. The trade was a 9.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Johnson sold 135,400 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $7.22, for a total transaction of $977,588.00. Following the completion of the sale, the director owned 698,083 shares of the company’s stock, valued at approximately $5,040,159.26. This trade represents a 16.25% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 280,217 shares of company stock worth $2,041,841. 6.47% of the stock is owned by company insiders.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in XERS. Royal Bank of Canada lifted its holdings in shares of Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares in the last quarter. Millennium Management LLC raised its position in Xeris Biopharma by 19.0% during the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after buying an additional 369,420 shares during the period. Goldman Sachs Group Inc. lifted its stake in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after acquiring an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP acquired a new stake in Xeris Biopharma during the 1st quarter worth about $170,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Up 1.4%

NASDAQ:XERS opened at $7.01 on Friday. The business’s 50-day moving average price is $7.27 and its 200 day moving average price is $7.52. Xeris Biopharma has a 52-week low of $3.44 and a 52-week high of $10.08. The firm has a market cap of $1.16 billion, a P/E ratio of -70.09 and a beta of 0.52.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.01). The firm had revenue of $74.38 million for the quarter, compared to the consensus estimate of $74.19 million. Sell-side analysts expect that Xeris Biopharma will post -0.41 EPS for the current year.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.